Literature DB >> 19117716

Surgical treatment of gastric cancer in Latvia: results of centralized experience.

A Sivins1, C Pedrazzani, F Roviello, G Ancans, M Timofejevs, A Pcholkins, V Krumins, V Boka, A Stengrevics, M Leja.   

Abstract

BACKGROUND: Although the mortality for gastric cancer is decreasing in Western Europe and United States, it still remains high in Eastern Europe. This study was aimed at evaluating short- and long-term results of surgical treatment of gastric cancer performed in Latvia Oncology Center.
METHODS: Retrospectively collected data from 461 patients who underwent gastrectomy with curative intent in Latvia Oncology Center from January 2001 to December 2005 were analyzed statistically.
RESULTS: An average (range) of 92.2 (81-102) R0-R1 gastrectomies was performed each year. Post-operative complications occurred in 75 patients (16.3%); in-hospital mortality was 3.3%. The overall 5-year survival was 50.8%. In 444 cases (96.3%) there was histopathologic confirmation of R0-resection with a 5-year survival of 52.5% (P<0.001). Considering pT category, 5-year survival was 88.6% for pT1 patients, 65% for pT2, 42.3% for pT3 and 27% for pT4 (P<0.001). Considering pN category, 5-year survival was 67% for pN0 patients, 30% for pN1 and 29% for pN2-3 (P<0.001).
CONCLUSIONS: Clinico-pathologic characteristics of patients who underwent resection with curative intent are comparable to other Western experiences. Short- as well as long-term results are also similar if not for pN+ patients where no difference between pN1 and pN2 cases was observed.

Entities:  

Mesh:

Year:  2008        PMID: 19117716     DOI: 10.1016/j.ejso.2008.11.006

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  1 in total

1.  Ratio between metastatic and examined lymph nodes (N ratio) may have low clinical utility in gastric cancer patients treated by limited lymphadenectomy: results from a single-center experience of 526 patients.

Authors:  Corrado Pedrazzani; Armands Sivins; Guntis Ancans; Daniele Marrelli; Giovanni Corso; Viesturs Krumins; Franco Roviello; Marcis Leja
Journal:  World J Surg       Date:  2010-01       Impact factor: 3.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.